FDA Sets High Bar for Prevention Agents as ODAC Votes Down Proscar And Avodart
Vanderbilt Wins NCI Core Grant Renewal with 12.7 Percent Funding increase
CTI Files Appeal Over FDA’s Decision on Pixantrone
NIH Defends NCI Sponsored Travel
Obituary: NCI’s Elaine Ron, Expert in Radiation Heath Effects
Trending Stories
- Karen Knudsen to leave ACS
- A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease
- Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies - Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Mace Rothenberg’s museum will tell the stories behind breakthroughs in medicine
- Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation